Group Discussion Deepens Over WHO Role In Stopping Poor Quality Medicines
The role of the World Health Organization in the safety, quality and efficacy of medical products is under scrutiny this week by member states and stakeholders. In particular, the focus is on the WHO’s role in the prevention and control of medical products of compromised quality, the organisation’s relationship with the international taskforce against counterfeit products, and the taskforce’s alleged focus on the protection of intellectual property rights rather than on public health issues. In several documents, the WHO tries to explain this fragile role.

On the eve of a meeting of the WHO working group on substandard/spurious/falsely-labelled/falsified/counterfeit medical products, research-based pharmaceutical industry group IFPMA sets out thoughts on building global consensus to address fake medicines.